Results for tag: "Rayaldee"

The Rayaldee market is a subset of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. Rayaldee is a vitamin D3 prohormone used to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD). It works by increasing the amount of active vitamin D in the body, which helps to reduce the amount of parathyroid hormone (PTH) in the blood. Rayaldee is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2016. It is currently the only FDA-approved drug for the treatment of SHPT in adults with stage 3 or 4 CKD. Some companies in the Rayaldee market include Otsuka Pharmaceuticals, which manufactures and markets the drug, as well as other pharmaceutical companies that are involved in the research and development of new treatments for SHPT. Additionally, there are a number of companies that specialize in the distribution and marketing of Rayaldee. Show Less Read more